Literature DB >> 7961519

Clozapine-induced transient white blood count disorders.

M Hummer1, M Kurz, C Barnas, A Saria, W W Fleischhacker.   

Abstract

BACKGROUND: The aim of the study was to shed more light on the incidence and course of clozapine-induced transient white blood count (WBC) disorders.
METHOD: In an analysis of our clozapine drug monitoring program, we evaluated the data of 68 patients receiving clozapine for the first time. Incidence rates were calculated by actuarial life table analysis. The potential influence of sex, age, dose, and plasma level was evaluated using discriminant analysis.
RESULTS: Two patients developed progressive neutropenia, leading to agranulocytosis in one case. We also found the following transient hematologic dysfunctions: neutropenia (22.0%), eosinophilia (61.7%), and leukocytosis (40.9%). One patient showed chronic leukocytosis. Additionally, minor changes in the number of lymphocytes, monocytes, and basophilic granulocytes were detected in the study population.
CONCLUSION: Hematologic side effects are frequently induced by the atypical antipsychotic clozapine. Next to agranulocytosis, a progressive and potentially lethal hematologic adverse effect, most of the WBC disorders are transient and appear to be harmless.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961519

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

Review 1.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.

Authors:  Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

Review 2.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Does eosinophilia predict clozapine induced neutropenia?

Authors:  M Hummer; B Sperner-Unterweger; G Kemmler; M Falk; M Kurz; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 4.  Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Authors:  Michael Berk; Joanna Fitzsimons; Timothy Lambert; Christos Pantelis; Jayashri Kulkarni; David Castle; Elizabeth W Ryan; Sean Jespersen; Pat McGorry; Gregor Berger; Bill Kuluris; Tom Callaly; Seetal Dodd
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Clozapine-induced blood dyscrasias in Saudi Arab patients.

Authors:  Norah O Abanmy; Afnan Al-Jaloud; Aisha Al-Jabr; Rana Al-Ruwaisan; Walaa Al-Saeed; Solafa Fatani
Journal:  Int J Clin Pharm       Date:  2014-06-12

6.  Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children.

Authors:  Anand Mattai; Lawrence Fung; Jennifer Bakalar; Gerald Overman; Julia Tossell; Rachel Miller; Judith Rapoport; Nitin Gogtay
Journal:  Hum Psychopharmacol       Date:  2009-10       Impact factor: 1.672

7.  Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment.

Authors:  Rajvi Patel; Ateaya Lima; Christopher Burke; Mark Hoffman
Journal:  BMJ Case Rep       Date:  2019-01-18

Review 8.  Management of schizophrenia in children and adolescents. The role of clozapine.

Authors:  H Remschmidt; C Fleischhaker; K Hennighausen; E Schulz
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.930

9.  Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis.

Authors:  Christina Voulgari; Raphael Giannas; Georgios Paterakis; Anna Kanellou; Nikolaos Anagnostopoulos; Stamata Pagoni
Journal:  Case Rep Med       Date:  2015-02-10

10.  Effect of Adenine on Clozapine-induced Neutropenia in Patients with Schizophrenia: A Preliminary Study.

Authors:  Ippei Takeuchi; Taro Kishi; Manako Hanya; Junji Uno; Kiyoshi Fujita; Hiroyuki Kamei
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.